Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.90 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.76 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.76 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313070 | 0.97 | HSP90AA1 (0.89) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312077 | 0.95 | HSP90AA1 (1.00) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL10185663 | 0.92 | HSP90AA1 (0.82) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312432 | 0.92 | HSP90AA1 (0.82) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL16569655 | 0.92 | HSP90AA1 (0.81) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL5550716 | 0.92 | HSP90AA1 (0.81) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312956 | 0.92 | HSP90AA1 (0.81) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL312603 | 0.91 | HSP90AA1 (1.00) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL5546172 | 0.91 | HSP90AA1 (0.85) | HSP90AA1TRAP1HSP90B1HSP90AB1 | |
| SCHEMBL14568087 | 0.90 | HSP90AA1 (0.73) | HSP90AA1TRAP1HSP90B1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1869027-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2007035963-A2 | ANTI-TUMOR METHODS USING MULTI DRUG RESISTANCE INDEPENDENT SYNTHETIC HSP90 INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
| WO-2006105372-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885TRAP1 8/4885HSP90B1 4/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885TRAP1 9/4885HSP90B1 4/4885 |
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885TRAP1 15/4885HSP90B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.